Document is current

Article History

Received: 18 October 2022

Accepted: 12 May 2023

First Online: 23 June 2023

Declarations

:

: Caicun Zhou reported honoraria as a speaker from Roche, Lily China, Boehringer Ingelheim, Merck, Hengrui, Qilu, Sanofi, Merck Sharp & Dohme, Innovent Biologics, C-Stone, Luye Pharma, TopAlliance Biosciences, and Amoy Diagnositics; and advisor fees for Innovent Biologics, Hengrui, Qilu, and TopAlliance Biosciences. Shengxiang Ren reported honoraria as a speaker from Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Roche, Hengrui, and Junshi, advisor fees for Roche, Merck Sharp & Dohme, and Boehringer Ingelheim and research funding from Hengrui. No other disclosures were reported.

: Not applicable.

: This study was approved by the ethics committee of Shanghai Pulmonary Hospital, Tongji University School of Medicine (ID: K18-136).